The study’s strengths include the nationwide cohort, the 1-year follow-up of the infants, the high degree of accuracy of the registry data on birth detects, and the use of prescription data, which eliminates the chance of recall bias, the authors said. The limitations included not being able to account for all confounding factors, such as ascertainment of maternal illnesses.
The study was funded by the Danish Medical Research Council. The authors reported having no relevant financial disclosures.
Fluconazole is marketed as Diflucan, ketoconazole is marketed as Nizoral, and itraconazole is marketed as Sporanox; all three are available in generic formulations.